Table 4.
A comparison of PVC-related symptom severity among XSN, mexiletine, and placebo group at baseline and 4 weeks after treatment, n (%).
| Items | Baseline | 4 weeks after treatment | ||||||
|---|---|---|---|---|---|---|---|---|
| XSN group (n=328) | Mexiletine group (n=336) | Placebo group (n=165) | P | XSN group (n=311) | Mexiletine group (n=326) | Placebo group (n=155) | P | |
| Palpitation | ||||||||
| None | 27 (8.23) | 23 (6.85) | 6 (3.64) | 0.6171 | 147 (47.27) | 114 (34.97) | 32 (20.65) | <0.0001 |
| Mild | 97 (29.57) | 118 (35.12) | 57 (34.55) | 145 (46.62) | 177 (54.29) | 93 (60.00) | ||
| Moderate | 178 (54.27) | 161 (47.92) | 84 (50.91) | 19 (6.11) | 31 (9.51) | 26 (16.77) | ||
| Severe | 26 (7.93) | 34 (10.12) | 18 (10.91) | 0 (0.00) | 4 (1.23) | 4 (2.58) | ||
| Chest discomfort | ||||||||
| None | 42 (12.80) | 40 (11.90) | 17 (10.30) | 0.9471 | 187 (60.13) | 171 (52.45) | 56 (36.13) | <0.0001 |
| Mild | 146 (44.51) | 163 (48.51) | 83 (50.30) | 118 (37.94) | 134 (41.10) | 82 (52.90) | ||
| Moderate | 136 (41.46) | 122 (36.31) | 62 (37.58) | 6 (1.93) | 21 (6.44) | 15 (9.68) | ||
| Severe | 4 (1.22) | 11 (3.27) | 3 (1.82) | 0 (0.00) | 0 (0.00) | 2 (1.29) | ||
PVC, premature ventricular contraction; P, XSN group vs. placebo group; XSN, Xin Su Ning.